Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

November 9, 2016

Immunotherapy Suggested as Best First-line Treatment for Advanced Melanoma

News

Combining immunotherapy options in patients diagnosed in advanced stages of cutaneous melanoma, a deadly skin cancer, improves survival and decreases the risk of serious adverse events, according to a new study ... Read more

October 13, 2016

Opdivo Promoted Cancer Regression In Patients With Metastatic Urothelial Carcinoma

News

Bristol-Meyer Squibb’s therapy Opdivo (nivolumab) improved cancer regression in patients with metastatic urothelial carcinoma resistant to platinum therapy, while maintaining the patients’ quality of life, according to the results of a ... Read more

October 12, 2016

Opdivo Stabilizes Health-Related Quality of Life in Head and Neck Cancer Patients, Study Shows

News

Bristol-Myers Squibb announced that their therapy Opdivo (nivolumab) improved health-related quality of life in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) following platinum chemotherapy, ... Read more

October 3, 2016October 3, 2016

Inhibitor, BGB324, May Strengthen Immunotherapy’s Effectiveness in Aggressive Cancers

News

BerGenBio AS’s BGB324, an inhibitor of a protein involved in tumor immune evasion, can enhance the effects of immune checkpoint inhibitors — such as anti-CTLA-4 and anti-PD-1 — in aggressive adenocarcinomas, ... Read more